Literature DB >> 11035927

Bone morphogenetic proteins secreted by breast cancer cells upregulate bone sialoprotein expression in preosteoblast cells.

P Bunyaratavej1, T G Hullinger, M J Somerman.   

Abstract

It is well established that bone metastases comprise bone; however, the exact factors/mechanisms involved remain unknown. We hypothesized that tumor cells secreted factors capable of altering normal bone metabolism. The aims of the present study were to (1) determine the effects of secretory products isolated from HT-39 cells, a human breast cancer cell line, on osteoprogenitor cell (MC3T3-E1 cells) behavior, and (2) identify tumor-derived factor(s) that alters osteoblast activities. Conditioned media (CM) from HT-39 cells were collected following a 24-h serum-free culture. The ability of CM to alter gene expression in MC3T3-E1 cells was determined by Northern analysis. CM effects on cell proliferation and mineralization ability were determined using a Coulter counter and von Kossa stain, respectively. MC3T3-E1 cells were treated with CM plus noggin, a factor known to block bone morphogenic proteins (BMPs), to determine whether BMPs, shown to be present in CM, were linked with CM effects on MC3T3-E1 cell activity. In addition, inhibitors of MAP kinase kinase (MEK), protein kinase C (PKC), and protein kinase A were used to identify the intracellular signaling pathway(s) by which the active factors in CM regulated osteoblast behavior. CM treatment significantly enhanced BSP mRNA (2.5-fold over control), but had no effect on cell proliferation. Mineralization assay showed that CM enhanced mineral nodule formation compared to controls. Noggin inhibited CM-induced upregulation of BSP mRNA, suggesting that BMPs were responsible for upregulating BSP gene expression in MC3T3-E1 cells. The PKC inhibitor blocked CM-mediated upregulation of BSP, suggesting involvement of the PKC pathway in regulating BSP expression. BMPs secreted by HT-39 cells may be responsible for enhancing BSP expression in MC3T3-E1 cells. Continued studies targeted at determining the role of BMPs in regulating bone metabolism are important for understanding the pathogenesis of bone diseases. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035927     DOI: 10.1006/excr.2000.5019

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  6 in total

1.  Metastatic breast cancer cells suppress osteoblast adhesion and differentiation.

Authors:  Robyn R Mercer; Chiaki Miyasaka; Andrea M Mastro
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

2.  Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway.

Authors:  Ya-Ling Hsu; Ming-Shyan Huang; Chih-Jen Yang; Jen-Yu Hung; Ling-Yu Wu; Po-Lin Kuo
Journal:  J Biol Chem       Date:  2011-09-01       Impact factor: 5.157

Review 3.  Honing Cell and Tissue Culture Conditions for Bone and Cartilage Tissue Engineering.

Authors:  Johnny Lam; Esther J Lee; Elisa C Clark; Antonios G Mikos
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

4.  Effects of bone morphogenetic protein-2 and transforming growth factor beta1 on gene expression of transcription factors, AJ18 and Runx2 in cultured osteoblastic cells.

Authors:  Minoru Takagi; Naoko Kamiya; Tomihisa Takahashi; Shinsuke Ito; Mitsuharu Hasegawa; Naoto Suzuki; Koji Nakanishi
Journal:  J Mol Histol       Date:  2004-01       Impact factor: 2.611

5.  Pre-osteoblastic MC3T3-E1 cells promote breast cancer growth in bone in a murine xenograft model.

Authors:  Thomas M Bodenstine; Benjamin H Beck; Xuemei Cao; Leah M Cook; Aimen Ismail; Should J Kent Powers; J Kent Powers; Andrea M Mastro; Danny R Welch
Journal:  Chin J Cancer       Date:  2011-03

Review 6.  Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance.

Authors:  Catherine Zabkiewicz; Jeyna Resaul; Rachel Hargest; Wen Guo Jiang; Lin Ye
Journal:  Endocr Relat Cancer       Date:  2017-07-21       Impact factor: 5.678

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.